|1.||Fujii, Nobutaka: 2 articles (12/2010 - 02/2003)|
|2.||Yuan, Fei: 1 article (01/2014)|
|3.||Jin, Jing: 1 article (01/2014)|
|4.||Yuan, Yuanzhi: 1 article (01/2014)|
|5.||Shen, Minqian: 1 article (01/2014)|
|6.||Sun, Zhongchan: 1 article (12/2013)|
|7.||Niu, Gang: 1 article (12/2013)|
|8.||Wang, Zhe: 1 article (12/2013)|
|9.||Kiesewetter, Dale O: 1 article (12/2013)|
|10.||Wu, Chenxi: 1 article (12/2013)|
02/01/2003 - "A highly selective CXCR4 antagonist, T22, and its downsized analogues T140 and TC14012, which inhibit X4-HIV-1 infection through their specific binding to CXCR4, have been identified. "
11/01/2001 - "The authors have discovered a highly selective CXCR4 antagonist, T22 ([Tyr5,12, Lys7]-polyphemusin II), and its shortened potent analogs, T140 and TC14012, which strongly inhibit the T-cell line-tropic HIV-1 (X4-HIV-1) infection through their specific binding to a chemokine receptor, CXCR4. "
12/01/2013 - "These results demonstrate that the [(18)F]FP-labeled Ac-TC14012 peptide with high tumor uptake, low nonspecific binding, and good tumor-to-background contrast promises [(18)F]FP-Ac-TC14012 as a PET tracer for in vivo PET imaging of CXCR4 expression."
12/01/2013 - "Among the two, [(18)F]FP-Ac-TC14012 showed higher tumor uptake and better tumor-to-background contrast. "
01/01/2014 - "TC14012 initially enhanced alkali burn-induced CNV but reduced CNV in later stages. "
01/01/2014 - "A total of 54 mice treated with alkali burns were randomly divided into 3 groups, each of which received one of the following treatments: bilateral subconjunctival injections of TC14012 for 3 consecutive days, bilateral subconjunctival injections of balanced saline (BS) for 3 consecutive days or no treatment (blank control). "
01/01/2014 - "To observe the effect of TC14012 (a CXCR4 antagonist and CXCR7 agonist) on alkali burn-induced corneal neovascularization (CNV) in a mouse model. "
01/01/2014 - "The effect of TC14012 on alkali burn-induced corneal neovascularization in mice."
01/01/2014 - "On day 7 after the alkali burns, the CNV area, VEGF, MMP-2 and MMP-9 mRNA levels, and VEGF, β-arrestin 2 and phospho-ERK1/2 protein levels were increased in the TC14012 group compared with the nontreatment and BS groups. "
|2.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|3.||CXCR4 Receptors (CXCR4 Receptor)
|5.||Messenger RNA (mRNA)